The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu,Patricia Pérez-Galán,Delong Liu,Angelique Biancotto,Stefania Pittaluga,Berengere Vire,Federica Gibellini,Ndegwa Njuguna,Elinor Lee,Lawrence S. Stennett,Nalini Raghavachari,Poching Liu,J. Philip McCoy,Mark Raffeld,Maryalice Stetler-Stevenson,Constance M. Yuan,Richard M. Sherry,Diane C. Arthur,Irina Maric,Therese White,Gerald E. Marti,Peter J. Munson,Wyndham H. Wilson,Adrian Wiestner +23 more
TLDR
The disruption of tumor microenvironment interactions and the inhibition of BCR signaling as promising therapeutic strategies in CLL are identified.About:
This article is published in Blood.The article was published on 2011-01-13 and is currently open access. It has received 776 citations till now. The article focuses on the topics: Chronic lymphocytic leukemia & BCR Signaling Pathway.read more
Citations
More filters
Journal ArticleDOI
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
TL;DR: The combination of idelalisib and rituximab, as compared with placebo and r ituximabs, significantly improved progression-free survival, response rate, and overall survival among patients with relapsed CLL who were less able to undergo chemotherapy.
Journal ArticleDOI
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
Ranjana H. Advani,Joseph J. Buggy,Jeff P. Sharman,Sonali M. Smith,Thomas E. Boyd,Barbara Grant,Kathryn S. Kolibaba,Richard R. Furman,Sara Rodriguez,Betty Y. Chang,Juthamas Sukbuntherng,Raquel Izumi,Ahmed Hamdy,Eric Hedrick,Nathan Fowler +14 more
TL;DR: Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies, consistent with the irreversible mechanism.
Journal ArticleDOI
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Bonnie K. Harrington,Susan O'Brien,Jeffrey A. Jones,Anna Schuh,S Devereux,Jorge M. Chaves,William G. Wierda,Farrukh T. Awan,Jennifer R. Brown,Peter Hillmen,Deborah M. Stephens,Paolo Ghia,Jacqueline C. Barrientos,John M. Pagel,Jennifer A. Woyach,Dave Johnson,Jane Huang,Xiaolin Wang,Allard Kaptein,Brian J. Lannutti,Todd Covey,Maria Fardis,Jesse McGreivy,Ahmed Hamdy,Wayne Rothbaum,Raquel Izumi,Thomas G. Diacovo,Amy J. Johnson,Richard R. Furman +29 more
TL;DR: In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.
Journal ArticleDOI
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
TL;DR: The results of the reported clinical trials are reviewed and the progress and key emerging factors that may play a role in effecting tumor responses are discussed, including managing toxicities and expanding the availability of personalized cell therapy as a promising approach to all hematologic malignancies.
Journal ArticleDOI
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo
Sabine Ponader,Shih Shih Chen,Joseph J. Buggy,Kumudha Balakrishnan,Varsha Gandhi,William G. Wierda,Michael J. Keating,Susan O'Brien,Nicholas Chiorazzi,Jan A. Burger +9 more
TL;DR: It is demonstrated that PCI-32765 effectively inhibits CLL cell migration and survival, possibly explaining some of the characteristic clinical activity of this new targeted agent.
References
More filters
Journal ArticleDOI
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Aravind Subramanian,Pablo Tamayo,Vamsi K. Mootha,Sayan Mukherjee,Benjamin L. Ebert,Michael A. Gillette,Amanda G. Paulovich,Scott L. Pomeroy,Todd R. Golub,Eric S. Lander,Jill P. Mesirov +10 more
TL;DR: The Gene Set Enrichment Analysis (GSEA) method as discussed by the authors focuses on gene sets, that is, groups of genes that share common biological function, chromosomal location, or regulation.
Journal ArticleDOI
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh,Michael B. Eisen,R. Eric Davis,Izidore S. Lossos,Andreas Rosenwald,Jennifer C. Boldrick,Hajeer Sabet,Truc Tran,Xin Yu,John Powell,Liming Yang,Gerald E. Marti,Troy Moore,James I. Hudson,Li-Sheng Lu,David B. Lewis,Robert Tibshirani,Gavin Sherlock,Wing C. Chan,Timothy C. Greiner,Dennis D. Weisenburger,James O. Armitage,Roger A. Warnke,Ronald Levy,Wyndham H. Wilson,M. R. Grever,John C. Byrd,David Botstein,Patrick O. Brown,Louis M. Staudt +29 more
TL;DR: It is shown that there is diversity in gene expression among the tumours of DLBCL patients, apparently reflecting the variation in tumour proliferation rate, host response and differentiation state of the tumour.
Journal ArticleDOI
Shared principles in NF-kappaB signaling
Matthew S. Hayden,Sankar Ghosh +1 more
TL;DR: The authors synthesize some of the basic principles that have emerged from studies of NF-kappaB, and aim to generate a more unified view of the regulation of the transcription factor.
Journal ArticleDOI
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Hartmut Döhner,Stephan Stilgenbauer,Axel Benner,Elke Leupolt,Alexander Kröber,Lars Bullinger,Konstanze Döhner,Martin Bentz,Peter Lichter +8 more
TL;DR: Genomic aberrations in chronic lymphocytic leukemia are important independent predictors of disease progression and survival and have implications for the design of risk-adapted treatment strategies.
Journal ArticleDOI
Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
Andrew Wotherspoon,Timothy C. Diss,Langxing Pan,Peter G. Isaacson,Claudio Doglioni,A. Moschini,M. de Boni +6 more
TL;DR: It is suggested that eradication of H pylori causes regression of low-grade B-cell gastric MALT lymphoma, and that anti-H-pylori treatment should be given for this lymphoma.
Related Papers (5)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more